온바디 인젝터 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

On-body Injectors Market Size, Share & Trends Analysis Report By Technology (Spring-based, Motor Driven), By Application (Oncology, Diabetes), By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,269,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,659,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,438,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

온바디 인젝터 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 온바디 인젝터 세계 시장 규모는 2024년부터 2030년까지 14.9%의 CAGR을 기록하여 2030년까지 127억 달러에 달할 것으로 예상됩니다.

체내 주사기는 사용이 간편하고 통증이 적으며 잦은 병원 방문 없이 장시간 약물을 투여할 수 있어 환자의 복약 순응도를 높일 수 있습니다. 이러한 장점으로 인해 체내 주사기의 인기가 높아지고 있습니다. 또한, 의료 인프라가 잘 갖추어져 있고 첨단 의료기기가 도입되고 있는 아시아태평양과 같은 지역은 예측 기간 동안 시장 성장에 큰 기회를 제공하고 있습니다.

주사바늘 찔림에 대한 우려 증가, 주사바늘 삽입, 약물 준비, 주사바늘 커버 및 폐기 관련 위험을 제거하여 환자와 의료진 모두의 안전을 강화할 필요성, 그리고 암과 같은 만성 질환의 유병률 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

WHO의 국제암연구소(IARC)에 따르면 2022년에는 약 2,000만 명이 암 진단을 받고 약 970만 명이 암으로 사망할 것으로 예상됩니다. 일부 암 및 기타 만성 질환의 치료에는 장기간에 걸쳐 빈번한 약물 주사가 필요합니다. 온바디 인젝터는 기존의 병원 방문이나 자가 주사에 비해 환자가 이러한 약물을 투여하는 데 더 편리하고 혼란이 적은 대안을 제공합니다.

온바디 인젝터 시장 보고서 하이라이트

• 기술별로는 스프링식이 2023년 40.89%로 가장 큰 매출 점유율을 차지했는데, 이는 안정적인 압력과 속도로 정확한 투약을 보장하기 때문입니다.
• 기술별로는 로터리 펌프가 높은 투약 제어성, 투약 실수 위험 최소화, 치료 효과 극대화로 인해 예측 기간 동안 15.1%의 CAGR로 급성장할 것으로 예상됩니다.
• 용도별로는 빈번한 투여가 필요한 제2형 당뇨병의 높은 유병률로 인해 당뇨병 분야가 2023년 가장 큰 매출 점유율을 차지했습니다.
• 용도별로는 다발성 경화증, 류마티스 관절염, 염증성 장질환(IBD) 등 만성 자가면역질환의 유병률 증가로 자가면역질환 분야가 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 당뇨병, 자가면역질환, 암과 같은 만성질환을 관리하기 위한 약물 자가 투여에 대한 선호도가 높아짐에 따라, 최종 용도 기준으로 2023년 홈케어 분야가 가장 큰 매출 비중을 차지했습니다.
• 2023년에는 북미가 33.17%의 점유율을 차지했습니다. 이는 주요 시장 기업의 존재, 재택 치료로의 전환 증가, 고급 체내 주사기에 대한 접근성 향상에 기인합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 온바디 인젝터 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 온바디 인젝터 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 온바디 인젝터 시장 : 기술별 추정·동향 분석

• 부문 대시보드
• 온바디 인젝터 시장 : 기술별 변동 분석
• 온바디 인젝터 시장 : 기술별 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 스프링 기반
• 모터 구동
• 로터리 펌프
• 확장 배터리
• 기타

제5장 온바디 인젝터 시장 : 용도별 추정·동향 분석

• 부문 대시보드
• 온바디 인젝터 시장 : 용도별 변동 분석
• 온바디 인젝터 시장 : 용도별 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 종양학
• 당뇨병
• 심혈관질환
• 자가면역질환
• 기타

제6장 온바디 인젝터 시장 : 최종 용도별 추정·동향 분석

• 부문 대시보드
• 온바디 인젝터 시장 : 최종 용도별 변동 분석
• 온바디 인젝터 시장 : 최종 용도별 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 병원·클리닉
• 재택 케어 환경
• 기타

제7장 온바디 인젝터 시장 : 지역별 추정·동향 분석

• 지역 대시보드
• 온바디 인젝터 시장 : 지역별 변동 분석
• 온바디 인젝터 시장 : 기술, 용도, 최종 용도별 지역 추정·동향 분석
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
• 북미
  • 북미의 온바디 인젝터 시장 추정과 예측, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 온바디 인젝터 시장 추정과 예측, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양의 온바디 인젝터 시장 추정과 예측, 2018-2030년
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 라틴아메리카의 온바디 인젝터 시장 추정과 예측, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카의 온바디 인젝터 시장 추정과 예측, 2018-2030년
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 상황

• 시장 진출 기업 분류
• 주요 기업 개요
  • West Pharmaceutical Services, Inc.
  • BD
  • Stevanato Group
  • Enable Injections
  • Nemera
  • Debiotech SA
  • AbbVie, Inc.
  • Coherus BioSciences, Inc.
  • Gerresheimer AG
  • E3D Elcam Drug Delivery Devices

ksm

영문 목차

영문목차

On-body Injectors Market Growth & Trends:

The global on-body injectors market size is expected to reach USD 12.7 billion by 2030, registering a CAGR of 14.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The on-body injectors increase patient adherence to medication by offering easy-to-use, less pain and enabling extended drug administration without frequent hospital visits. These advantages of on-body injectors are significantly increasing their popularity. Moreover, regions such as Asia Pacific, with developing healthcare infrastructure and rising adoption of advanced medical devices, offer huge opportunities for market growth over the forecast period.

The increasing concerns over needle stick injuries and the need to increase the safety for both patients and healthcare professionals by eliminating risks associated with needle insertion, drug preparation, and covering & disposing of needles, coupled with the increasing prevalence of chronic diseases such as cancer are some of the factors expected to drive the market growth over the forecast period.

According to the WHO agency International Agency for Research on Cancer (IARC), around 20 million people were diagnosed with cancer, and around 9.7 million mortalities occurred due to cancer in 2022. Several cancers and other chronic disease treatments require frequent injections of medications over extended periods. On-body injectors offer a convenient and potentially less disruptive alternative for patients to receive these medications compared to traditional hospital visits or self-administered injections, which can significantly increase their demand over the forecast period.

On-body Injectors Market Report Highlights:

• Based on the technology, the spring-based segment accounted for the largest revenue share of 40.89% in 2023 owing to their consistent pressure and speed, which ensures precise dosing
• Based on technology, the rotary pump segment is expected to grow at the fastest CAGR of 15.1% during the forecast period owing to the high control offered by them in dispensing medications, minimizing the risk of dosing errors and maximizing therapeutic efficacy
• Based on the application, the diabetes segment accounted for the largest revenue share in 2023 due to the high prevalence of type 2 diabetes, which requires frequent administration
• Based on the application, the autoimmune diseases segment is expected to grow at the fastest CAGR owing to the rising prevalence of chronic autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and Inflammatory Bowel Diseases (IBD)
• Based on the end use, the homecare segment accounted for the largest revenue share in 2023 owing to the growing preference for self-administration of medications for managing chronic conditions such as diabetes, autoimmune disorders, and cancer in homecare settings
• In 2023, North America dominated with a share of 33.17%, driven by the presence of key market players, an increasing shift toward home care, and better access to advanced on-body injectors

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.1. Segment Definitions
  • 1.1.1. Technology
  • 1.1.2. Application
  • 1.1.3. End Use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecasts timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. On-body Injectors Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Patient preference and compliance
    • 3.2.1.4. Increasing focus on home healthcare
    • 3.2.1.5. Increasing concerns about needlestick injuries
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost compared to alternatives
• 3.3. On-body Injectors Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. On-body Injectors Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. On-body Injectors Market: Technology Movement Analysis
• 4.3. On-body Injectors Market by Technology Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Spring-based
  • 4.5.1. Spring-based Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Motor-driven
  • 4.6.1. Motor-driven Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Rotary Pump
  • 4.7.1. Rotary Pump Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Expanding Battery
  • 4.8.1. Expanding Battery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Other
  • 4.9.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. On-body Injectors Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. On-body Injectors Market: Application Movement Analysis
• 5.3. On-body Injectors Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Oncology
  • 5.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Diabetes
  • 5.6.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Cardiovascular Disease
  • 5.7.1. Cardiovascular Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Autoimmune Disease
  • 5.8.1. Autoimmune Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. On-body Injectors Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. On-body Injectors Market: End Use Movement Analysis
• 6.3. On-body Injectors Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospitals & Clinics
  • 6.5.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Home Care Settings
  • 6.6.1. Home Care Settings Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. On-body Injectors Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional On-body Injectors Market movement analysis
• 7.3. On-body Injectors Market: Regional Estimates & Trend Analysis by Technology, Application & End Use
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. North America
  • 7.5.1. North America On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. UK On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Germany On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. France On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Italy On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Spain On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Denmark
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Denmark On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Sweden On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.9. Norway
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Competitive Scenario
    • 7.6.9.3. Regulatory Framework
    • 7.6.9.4. Reimbursement scenario
    • 7.6.9.5. Norway On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Japan
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Japan On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. China On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. India On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Australia On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Thailand On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. Brazil
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Brazil On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Argentina On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Middle East & Africa
  • 7.9.1. Middle East & Africa On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.2. South Africa
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. South Africa On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. Saudi Arabia On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. UAE On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Competitive Scenario
    • 7.9.5.3. Regulatory Framework
    • 7.9.5.4. Reimbursement scenario
    • 7.9.5.5. Kuwait On-body Injectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. West Pharmaceutical Services, Inc.
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. BD
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Stevanato Group
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Enable Injections
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Nemera
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Debiotech SA
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. AbbVie, Inc.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Coherus BioSciences, Inc.
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Gerresheimer AG
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. E3D Elcam Drug Delivery Devices
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives

관련자료